Scandinavian ChemoTech AB (publ) brings forward interim report

Scandinavian ChemoTech AB (publ) ("ChemoTech") has decided to bring forward the publication of the interim report for the third quarter to 17 October 2023.

The interim report for the third quarter was previously scheduled for November 7, 2023, but is moved to October 17, 2023.

The reason for the change of date is that the completion of the interim report has been faster than expected, and that the Board of Directors believes that it is of value for shareholders and investors to be able to access as complete financial information as possible during the rights issue decided by the Board of Directors on October 9, 2023 with a subscription period between October 18, 2023 and November 8, 2023.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.